Fc receptors specifically bind to the Fc region of Igs to mediate the unique functions to each class of Igs. To identify a novel Fc receptor for IgM, we searched expressed sequence tag database for molecules containing Ig domains with homology to those of known Fc receptors for IgM, Fca/mR and polymeric Ig receptor. As a result, we identified TOSO/Fas apoptotic inhibitory molecule 3 (FAIM3) as a possible Fc receptor for IgM. HeLa cells transfected with a TOSO/FAIM3-expression vector bound to IgM but not IgG and were able to internalize IgM-conjugated beads but not IgG-conjugated beads, suggesting that TOSO/FAIM3 is indeed a receptor for IgM (FcmR). FcmR protein was expressed predominantly on B-lineage cells; expression of the Fcmr transcripts was observed from the pre-B-cell stage and maintained thereafter during B-cell development. These results identify TOSO/FAIM3 as a receptor for IgM and suggest that FcmR may serve as an uptake receptor for IgM-opsonized antigens by B cells.
Introduction
Antibodies define humoral immunity and translate specific antigen recognition to diverse effector functions in the immune system. There are two major functional domains in Igs that were originally defined by proteolytic digestion studies, the Fab (fragment antigen binding) and the Fc (fragment crystallizable). The Fab fragment determines the antigen specificity for a given Ig, whereas the Fc fragment confers antibody effector functions, e.g. by binding to cellular Fc receptors. Igs are divided into five main classes in mammals based on the differences in amino acid sequence of their Fc fragments, namely IgM, IgG, IgA, IgE and IgD. Fc receptors have been identified that specifically recognize each class of Ig, except for IgD. Each Fc receptor is distinctly distributed mainly among hematopoietic cells and has been shown to possess unique immunological functions (1) (2) (3) .
Among them, two receptors have been shown to bind to IgM, namely Fca/lR (4) and the polymeric Ig receptor (pIgR) (5, 6) . Both Fca/lR and pIgR can bind to IgA and IgM with intermediate affinity, and the genes encoding these receptors are present within the same chromosomal region on chromosome 1 both in humans and mice. Fca/lR is expressed by mature B cells, macrophages and follicular dendritic cells in the secondary lymphoid organs such as lymph nodes and Peyer's patches in the intestine and is suggested to possess a range of immunoregulatory function (4, 7, 8) . On the contrary, pIgR is predominantly expressed on the basolateral plasma membrane of mucosal epithelial cells and plays a role in the delivery of secretory IgA and IgM across the epithelial layer to the mucosal lumen (6, 9, 10) . Although the existence of an Fc receptor uniquely specific for IgM has long been suggested (1, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , its genetic identity has not been elucidated.
In search of as yet unidentified Fc receptors for IgM, we took advantage of large databases of expressed sequence tags (ESTs) to identify genes encoding Ig domains with homology to those of pIgR and Fca/lR. In this paper, we report the identification and molecular characterization of TOSO/ Fas apoptotic inhibitory molecule 3 (FAIM3) as a novel IgM receptor (FclR).
Methods

Animals
C57BL/6J mice of 7-10 weeks old were obtained from CLEA Japan. All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals in RIKEN.
Complementary DNA cloning and plasmid vector construction
Human and mouse TOSO/FAIM3 complementary DNAs (cDNAs) were obtained from Integrated Molecular Analysis of Genomes and their Expression consortium (cDNA clone ID: 4852791) and RIKEN FANTOM (clone accession number: AK007714), respectively. Mouse Fca/lR cDNA was cloned by PCR amplification of oligo-dT-primed spleen cDNA of C57BL/6J mice. Mammalian expression vectors for C-terminally hemagglutinin (HA)-tagged FAIM3 and Fca/lR were constructed into BamHI and XhoI sites of pcDNA3-HAC, as described previously (23) .
To establish mAbs against FAIM3, a cDNA fragment corresponding to the extracellular domains of mouse FclR was amplified by PCR using primers 5#-GCAGATCTATGAGAGTC CTCCCAGAAGTAC-3# and 5#-CTACTCGAGAAATTCTGGGA TGGGGATGTG-3#. The obtained cDNA fragment was inserted into the BamHI/XhoI cloning sites of a modified pcDNA3 expression vector containing an XhoI/XbaI fragment encoding the Fc segment of human IgG1 (pcDNA3-mFclR-Fc).
Antibodies
The mFclR-Fc fusion protein was purified with a protein A Sepharose column from culture supernatant of HEC293T cells transfected with pcDNA3-mFclR-Fc. Anti-mouse FclR mAbs were generated by fusing the P3U1 myeloma cell line with popliteal lymph node cells from Wistar rats that had been immunized by injecting into their footpads the purified mFclRFc protein as an antigen. The specificity of the FclR mAb was confirmed by surface staining of control HeLa or HeLa cells transfected with an FclR expression vector, as well as by staining of B cells from wild type and FclR-knockout mice.
Rat anti-HA mAb (3F10) was purchased from Roche Diagnostics. Cy3-conjugated anti-rat IgG secondary antibody and HRPconjugated anti-rabbit IgG secondary antibody were purchased from Jackson ImmunoResearch Laboratories. Mouse Igs, IgA (M18-254) and IgM (TEPC183) were purchased from BD Biosciences, and mouse IgG were from Jackson Immunolaboratories. The following FITC-, PE-or biotin-conjugated mAbs were purchased from eBioscinece: anti-B220 (RA3-6B2), anti-CD3 (2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD19 (1D3), anti-CD21/CD35 (4E3), anti-F4/80 (BM8), anti-CD11c (N418), anti-CD11b (M1/70), anti-IgM (R6-60.2) and anti-IgD (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) .
Northern blot analysis
A human multiple RNA blot (Clontech) was hybridized with a 32 P-labeled cDNA fragment of human FclR according to the manufacturer's instructions. The human b-actin cDNA control probe was provided by the manufactures. 18 .81 and 70Z/13; immature B cells, CH31; mature B cells, A20/2J and WEHI279). The first-strand cDNA was synthesized with ReverTra Ace-a (TOYOBO) using oligo-dT 20 primer. The pro-B, pre-B and immature B cells were sorted from BM as described previously (24) . The germinal center B, follicular B, marginal zone B and the newly formed B cells were sorted as described (25) .
Reverse transcription-PCR analysis
All procedures were performed in accordance with the according to the manufacturer's instructions. Primers used for amplification of mouse FclR cDNA fragments were as follows: 5#-CTCGGATCCATTATCATCGAATGCC-3# and 5#-ATACTCGA GCTGGGATGTTCACTCCC-3#. glyceraldehyde-3-phosphate dehydrogenase primers were described elsewhere (26) .
Ig uptake assay
Mouse Igs, IgA, IgM and IgG, were covalently conjugated with yellow-green fluorescent 0.2-lm microsphere beads (F-8811, Molecular Probe) using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide as a catalyst. The detailed protocol is available on the manufacturer's website: http://www.probes.invitrogen. com/media/pis/mp05001.pdf. HeLa cells were transfected with the expression vectors for human and mouse FclR tagged with the C-terminal HA-epitope, using FuGene6 transfection reagent. As a control, mouse Fca/lR was also transfected. The transfected cells were cultured for 24 h and then incubated for 1 h at 37°C with mouse Ig-conjugated microbeads. The cells were washed twice with PBS and fixed with 4% paraformaldehyde/PBS for 30 min at room temperature and then permeabilized with 0.1% Triton X-100/ PBS and incubated for 1 h at room temperature with anti-HA (3F10) antibody. The cells were washed twice with PBS and stained with Cy3-conjugated anti-rat IgG secondary antibody. The stained cells were observed with a DM-IRE2 confocal laser scanning microscope and Leica confocal software (Leica Microsystems).
Flow cytometric analysis
Mouse splenocytes were incubated in FACS buffer (2% FCS in PBS) with anti-CD 16/32 (clone94) for 15 min and then the cells were stained with anti-mouse FclR mAb (clone #4B5) in combination with FITC-or Cy3-conjugated anti-rat IgG secondary antibody. The cells were further stained with various FITC-, PE-or biotin-conjugated antibodies in combination with PECy7-conjugated streptavidin. The stained cells were analyzed using a FACSCalibur with CellQuest software (BD Biosciences).
Results
Screening of a novel Fc receptor
We used a bioinformatics approach to identify novel Fc receptors for IgA and/or IgM. We performed EST database searches to identify genes containing Ig domains with homology to the Ig domain of pIgR, Fca/lR and CD300 antigenlike family member G (CD300LG), another Ig receptor-like protein exclusively expressed on capillary endothelium (23) . As a result, TOSO/FAIM3 was found to possess an Ig domain that shared ;36, 36 and 29% amino acid identities with those of pIgR, Fca/lR and CD300LG proteins, respectively ( Fig. 1A and Table 1 ). In addition, the mouse TOSO/ FAIM3 protein possessed 57.7% homology with human TOSO/FAIM3 protein (Fig. 1B) , whereas the coding region of mouse Toso/Faim3 gene shared 70.2% homology with that of human TOSO/FAIM3 gene (data not shown). Multiple serine and tyrosine residues are contained in the cytoplasmic region and may play a role in signal transduction by the FclR. Several asparagine (N ) residues are also present but do not match the consensus N-X-S/T motif known to be the preferred substrate for N-glycosylation (27) and it remains to be determined whether these residues actually undergo glycosylation. There are several serine and threonine residues that could potentially undergo O-glycosylation. Furthermore, we found that the TOSO/FAIM3 gene is clustered with PIGR and FCAMR on chromosome 1 both in human and mouse (Fig. 1C) , in support of the possibility that Toso encodes an Fc receptor. In addition, Toso encodes a 60-kDa type I integral membrane protein with an Ig-like domain. Taken (Fig. 2) . In addition, mouse IgM-conjugated microbeads, but not IgA-or IgG-conjugated microbeads, were specifically taken up by HeLa cells expressing either mouse or human TOSO/FAIM3 (Fig. 3A and B) . As an additional control, IgA-and IgM-conjugated microbeads bound to and were taken up by Fca/lR-expressing-HeLa cells, whereas IgG-conjugated microbeads were not (Fig. 3C) . Taken together with the homology with Fca/lR and pIgR, these observations indicate that TOSO/FAIM3 is an Fc receptor for IgM, and we therefore designate it as FclR in this manuscript.
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FclR is predominantly expressed on B lymphocytes
To examine the tissue distribution of FclR, we performed northern blot and reverse transcription (RT)-PCR analysis of several human and mouse tissues. Human FCMR mRNA was strongly expressed in hematopoietic tissues such as the spleen, thymus and peripheral blood leukocytes (Fig. 4A) . Similarly, higher levels of mouse Fcmr transcript were detected in the spleen and thymus, as well as in BM and lymph node (Fig. 4B ). These observations indicate that FclR is predominantly expressed in immune cells.
We further examined the levels of mouse Fcmr transcripts by RT-PCR in sorted subpopulation of immune cells as well as in B-lineage cell lines. We found that Fcmr transcripts are strongly expressed in B220 + B cells, faintly expressed in CD11b + and CD11c + myeloid/DC populations and barely detectable in T cells isolated from the spleen (Fig 5A) . Analysis of BM subpopulation as well as B cell lines representing different differentiation stages revealed that the expression of Fcmr was initiated from the stage of pre-B cells and maintained thereafter (Fig. 5B and C) . To corroborate the cellular distribution of FclR at the protein level, we performed FACS analysis of spleen cells. As shown in Fig. 6 
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These expression patterns of mouse FclR during B-cell development and differentiation implicate a potential role for FclR in B-cell maturation and/or function. It is also known that chronic lymphocytic leukemia cells express increased levels of FclR compared with healthy B cells (29) and that its expression in the leukemia cells is controlled by B-cell receptor signaling (30) . These observations may suggest a role for FclR in B-cell receptor signaling and/or B-cell activation as well.
FclR was initially identified as an inhibitor for Fasmediated apoptosis when over-expressed in T cells (31) . Subsequently, inhibition of Fas-mediated apoptosis was shown to involve binding of the cytoplasmic region of FclR with Fasassociated death domain (32) . FclR was also shown to be involved in IL-2-mediated activation-induced cell death in human T cells (33) . These observations suggest that FclR could protect human T cells from Fas-mediated apoptosis under certain conditions. However, we have recently found that human FclR itself has no inhibitory activity in Fas-mediated apoptosis when an anti-Fas antibody of an IgG isotype is used (28) . The inhibition is only achieved with IgM isotype anti-Fas antibody, strongly suggesting that the simultaneous binding of the anti-Fas antibody of IgM isotype to both Fas and FclR affected the apoptosis-inducing activity. It is of note that human FclR is expressed on T cells in addition to B cells (28) . Therefore, the expression pattern of FclR is not identical between human and mice, which may suggest species-specific functions. However, it is possible that mouse T cells may express FclR under certain conditions, for example, upon activation. Further studies are required to clarify the differential regulation of FclR expression in B and T cells.
It has also been reported that enzymatically modified lowdensity lipoprotein up-regulates FAIM3 (FCMR) transcript levels in human macrophages and enhances the survival of these cells (34) . Consistent with this observation, we detected Fcmr transcripts in macrophages and dendritic cells derived from mouse spleen, although no surface expression of FclR on these cells could be detected (data not shown). It is possible that FclR expression in these cells is regulated both at the transcriptional and posttranscriptional levels and that certain activation signals may induce cell surface FclR expression. A future issue to be resolved is whether IgM binding to FclR modulates the survival of these cells upon activation. Recently, we have successfully established FclR-knockout mice, which are fertile and show no grossly apparent abnormalities. This is in contrast to the finding by Song et al. (32) who indicated in the discussion of their paper that FclR deficiency is embryonically lethal. Detailed analyses of these mice are now in progress and will 
